13F filer · CIK 1536054
Crestline Management, L.P.
FORT WORTH, TX · filing since Q4 2014 · last filing Aug 14, 2026
Reported value
$53.5M
+$7.2M vs prior
Positions
3
New / sold out
0 / 0
Added / reduced
0 / 1
Turnover
0.0%
buys $0 · sells $7.7M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
No new or increased positions this quarter.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | DENALI THERAPEUTICS INC | -300,000 | -13.6% | $-7.7M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | DENALI THERAPEUTICS INCCOM | 1,910,732 | $49.1M | 91.90% |
| 2 | SANA BIOTECHNOLOGY INCCOM | 755,736 | $2.6M | 4.93% |
| 3 | 8X8 INC NEWCOM | 990,850 | $1.7M | 3.17% |